Black Bird Biotech, Inc. Stock

Equities

BBBT

US09183V1017

Pharmaceuticals

Market Closed - OTC Markets 01:35:46 2024-04-24 pm EDT 5-day change 1st Jan Change
0.0002 USD 0.00% Intraday chart for Black Bird Biotech, Inc. 0.00% +100.00%
Sales 2021 0.1 Sales 2022 0.08 Capitalization 188K
Net income 2021 -1M Net income 2022 -1M EV / Sales 2021 59,667,541 x
Net cash position 2021 436K Net Debt 2022 749K EV / Sales 2022 11,349,273 x
P/E ratio 2021
-2.42 x
P/E ratio 2022
-0.15 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 55.12%
More Fundamentals * Assessed data
Dynamic Chart
Black Bird Biotech, Inc. Appoints Nelson Grist as New CEO CI
Black Bird Biotech, Inc. Appoints Nelson Grist as Its Future Member of Its Board of Directors CI
Black Bird Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Black Bird Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Black Bird Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Black Bird Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Black Bird Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Black Bird Biotech, Inc. Auditor Raises 'Going Concern' Doubt CI
Black Bird Biotech, Inc. announced that it expects to receive $5 million in funding from Mast Hill Management, LLC CI
Black Bird Biotech Secures Distribution Agreement for Its MiteXstream Biopesticide CI
Black Bird Biotech Hires XCPCNL Business Services Corporation to Boost Bee Tested, Bee Safe Mitexstream Biopesticide Sales Within Cannabis Industry CI
Black Bird Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Black Bird Biotech To Formally Test MiteXstream Biopesticide for Capacity to Boost Plant Growth, Fruit Production, In Common Agricultural Crops CI
Black Bird Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Black Bird Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
More news
Current month+100.00%
3 months+100.00%
6 months+100.00%
Current year+100.00%
More quotes
1 week
0.00
Extreme 0.0001
0.00
1 month
0.00
Extreme 0.0001
0.00
Current year
0.00
Extreme 0
0.00
1 year
0.00
Extreme 0
0.00
3 years
0.00
Extreme 0
0.07
5 years
0.00
Extreme 0
0.28
10 years
0.00
Extreme 0
0.28
More quotes
Date Price Change Volume
24-04-24 0.0002 0.00% 3,550,000
24-04-23 0.0002 0.00% 2,000,000
24-04-22 0.0002 0.00% 2,090,000
24-04-19 0.0002 +33.33% 20,251,391
24-04-18 0.00015 0.00% 21,922,051

Delayed Quote OTC Markets, April 24, 2024 at 01:35 pm EDT

More quotes
Black Bird Biotech, Inc. is a manufacturer and distributor for MiteXstream, an environmental protection agency (EPA)-certified plant-based biopesticide effective in the eradication of mites and other similar pests, including spider mites, that destroy crops, particularly cannabis, hops, coffee and house plants, as well as molds and mildew. The Company also manufactures and sells, under its Grizzly Creek Naturals brand name, cannabidiol (CBD) products, including CBD Oils, gummies and pet treats, as well as CBD-infused personal care products. Big Sky American Dist., LLC (Big Sky American) distributes its Grizzly Creek Naturals products, as well as an array of other consumer retail products, in Western Montana. The Company's subsidiaries include Black Bird Potentials Inc. (BB Potentials), Big Sky American Dist., LLC (Big Sky American) and Black Bird Hemp Manager, LLC.
More about the company